ELI LILLY & Co
ELI LILLY & Co (LLY): 228 pipeline candidates · 81 upcoming catalysts · ~9 mo cash runway · 424 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.4 months
N/A
Lead: Approved
228 candidates
81 upcoming, next in ~13d
0 buys · 36 sells (180d)
A transparent, data-derived signal for ELI LILLY & Coacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$994.1B
Cash
$5.3B
Quarterly Burn
$6.4B
Runway
9.4 mo
Revenue
$19.8B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (228 candidates)
| Drug | Phase |
|---|---|
| [¹⁴c]-ly3502970 | Phase 1 |
| [ga-68]-pnt6555 | Phase 1 |
| [Lu-177]-PNT2002 | Phase 3 |
| [lu-177]-pnt6555 | Phase 1 |
| Abiraterone | Phase 3 |
| adalimumab | Phase 3 |
| adcirca | Approved |
| Alimta® | Approved |
| Antiretroviral Therapy | Phase 2 |
| Background Chemotherapy | Phase 2 |
Showing 10 of 228 candidates. Sign up for full pipeline.
Upcoming Catalysts (81)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4,330
Total value held
$723.41B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 106,723,548 | $98.16B |
| lilly endowment inc | 91,896,978 | $84.52B |
| blackrock, inc. | 66,493,842 | $61.16B |
| pnc financial services group, inc. | 51,328,908 | $47.21B |
| state street corp | 35,610,002 | $32.75B |
| fmr llc | 26,341,031 | $24.23B |
| vanguard portfolio management llc | 20,977,027 | $19.29B |
| geode capital management, llc | 20,191,864 | $18.51B |
| morgan stanley | 15,437,458 | $14.20B |
| wellington management group llp | 13,427,061 | $12.35B |
Showing top 10 of 4,330 institutional holders of ELI LILLY & Co. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ELI LILLY & Co's pipeline?
ELI LILLY & Co (LLY) has 228 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ELI LILLY & Co's lead drug candidate?
ELI LILLY & Co's most advanced tracked candidate is [¹⁴c]-ly3502970 (Phase 1) for Healthy.
What is ELI LILLY & Co's next catalyst?
ELI LILLY & Co's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Ch" — expected July 1, 2026.
What is ELI LILLY & Co's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ELI LILLY & Co has approximately 9.4 months of cash runway.
What is ELI LILLY & Co's market capitalization?
ELI LILLY & Co's market capitalization is approximately $994.1B.
Get the full picture on ELI LILLY & Co
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.